Clinical Trials
45 trialsPhase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Fox Chase Cancer Center
TARSARC
Institut Bergonié
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
City of Hope Medical Center
ANTARES
Instituto do Cancer do Estado de São Paulo
A Study of Ivonescimab in People With Leiomyosarcoma
Memorial Sloan Kettering Cancer Center
DAPPER
University Health Network, Toronto
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
University of Colorado, Denver
PROSARC-1
Oslo University Hospital
PROSARC-2
Oslo University Hospital
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma
Northwestern University
TAIS
Fudan University
PEMBROSARC
Institut Bergonié
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Memorial Sloan Kettering Cancer Center
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Ohio State University Comprehensive Cancer Center
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
DiTuSarc
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
M.D. Anderson Cancer Center
APX005M and Doxorubicin in Advanced Sarcoma
Columbia University
TAGGED
Sarcoma Oncology Research Center, LLC
A Study of Nivolumab in Selected Uterine Cancer Patients
Memorial Sloan Kettering Cancer Center
PazoDoble
North Eastern German Society of Gynaecological Oncology
ATX-101
Columbia University
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Niraparib for the Treatment of Leiomyosarcoma
Ohio State University Comprehensive Cancer Center
M6620 (VX-970) in Selected Solid Tumors
Massachusetts General Hospital
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Brown University
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Brown University
SINDIR
Maria Sklodowska-Curie National Research Institute of Oncology
UN-RESARC
Maria Sklodowska-Curie National Research Institute of Oncology
Vorinostat (SAHA) in Uterine Sarcoma
Medical University of Graz
LMS03
UNICANCER
SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
Sarcoma Alliance for Research through Collaboration
Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
M.D. Anderson Cancer Center
TAUL
Mario Negri Institute for Pharmacological Research
Bevacizumab and Radiation Therapy for Sarcomas
Massachusetts General Hospital
Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
Dana-Farber Cancer Institute
Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors
AGO Study Group
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
UNICANCER
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Memorial Sloan Kettering Cancer Center
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Memorial Sloan Kettering Cancer Center
Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Sarcoma Alliance for Research through Collaboration
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
H. Lee Moffitt Cancer Center and Research Institute